Share-based Payment Arrangement, Expense of Moleculin Biotech, Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Moleculin Biotech, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Moleculin Biotech, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $303,000, a 14% decline year-over-year.
  • Moleculin Biotech, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,632,000, a 8.2% decline year-over-year.
  • Moleculin Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,726,000, a 13% decline from 2023.
  • Moleculin Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,984,000, a 13% decline from 2022.
  • Moleculin Biotech, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,275,000, a 4.1% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Moleculin Biotech, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,632,000 $303,000 -$50,000 -14% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $1,682,000 $417,000 -$36,000 -7.9% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $1,718,000 $485,000 -$8,000 -1.6% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $1,726,000 $427,000 -$52,000 -11% 01 Oct 2024 31 Dec 2024 10-K 21 Mar 2025 2024 FY
Q3 2024 $1,778,000 $353,000 -$140,000 -28% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $1,918,000 $453,000 -$60,000 -12% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $1,978,000 $493,000 -$6,000 -1.2% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $1,984,000 $479,000 -$56,000 -10% 01 Oct 2023 31 Dec 2023 10-K 21 Mar 2025 2024 FY
Q3 2023 $2,040,000 $493,000 -$206,000 -29% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $2,246,000 $513,000 -$1,000 -0.2% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $2,247,000 $499,000 -$28,000 -5.3% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $2,275,000 $535,000 -$23,000 -4.1% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
Q3 2022 $2,298,000 $699,000 -$278,000 -28% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $2,576,000 $514,000 +$81,000 +19% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $2,495,000 $527,000 +$122,000 +30% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $2,373,000 $558,000 +$143,000 +34% 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $2,230,000 $977,000 +$517,000 +112% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,713,000 $433,000 +$25,000 +6.1% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $1,688,000 $405,000 +$8,000 +2% 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022 2022 Q1
Q4 2020 $1,680,000 $415,000 +$33,000 +8.6% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $1,647,000 $460,000 -$29,000 -5.9% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $1,676,000 $408,000 +$90,000 +28% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $1,586,000 $397,000 +$49,000 +14% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q4 2019 $1,537,000 $382,000 +$67,000 +21% 01 Oct 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
Q3 2019 $1,470,000 $489,000 +$245,000 +100% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $1,225,000 $318,000 -$21,000 -6.2% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $1,246,000 $348,000 +$106,000 +44% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $1,140,000 $315,000 +$94,000 +43% 01 Oct 2018 31 Dec 2018 10-K 19 Mar 2020 2019 FY
Q3 2018 $1,046,000 $244,000 -$22,000 -8.3% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $1,068,000 $339,000 +$229,000 +208% 01 Apr 2018 30 Jun 2018 10-Q 16 Aug 2019 2019 Q2
Q1 2018 $839,000 $242,000 +$132,000 +120% 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1
Q4 2017 $707,000 $221,000 01 Oct 2017 31 Dec 2017 10-K 21 Feb 2019 2018 FY
Q3 2017 $266,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $110,000 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018 2018 Q2
Q1 2017 $110,000 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1

Moleculin Biotech, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,726,000 -$258,000 -13% 01 Jan 2024 31 Dec 2024 10-K 21 Mar 2025 2024 FY
2023 $1,984,000 -$291,000 -13% 01 Jan 2023 31 Dec 2023 10-K 21 Mar 2025 2024 FY
2022 $2,275,000 -$98,000 -4.1% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
2021 $2,373,000 +$693,000 +41% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $1,680,000 +$143,000 +9.3% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $1,537,000 +$397,000 +35% 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021 2020 FY
2018 $1,140,000 +$433,000 +61% 01 Jan 2018 31 Dec 2018 10-K 19 Mar 2020 2019 FY
2017 $707,000 +$383,000 +118% 01 Jan 2017 31 Dec 2017 10-K 21 Feb 2019 2018 FY
2016 $324,000 01 Jan 2016 31 Dec 2016 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.